REG - Trellus Health PLC - Agreement with Johnson & Johnson

Trellus HealthAnnouncement

14/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250114:nRSN2349Ta&default-theme=true

RNS Number : 2349T  Trellus Health PLC  14 January 2025

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Trellus Health to Bring Holistic Support to Patients, Working With a
Pharmaceutical Company

 

LONDON, U.K. AND NEW YORK, U.S. (14 January 2025). Trellus Health plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate™, a digital platform
that integrates data analytics with personalized, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, announced it has entered into an agreement with Johnson &
Johnson Health Care Systems Inc. to support a pilot in the US to assess the
potential for the Trellus Elevate program to support patients with moderately
to severely active inflammatory bowel disease (IBD).

 

As part of the agreement, Trellus Health® will receive an undisclosed upfront
licensing fee, along with a fixed monthly management fee. The one-year
collaboration will provide eligible patients prescribed a Johnson &
Johnson therapy access to Trellus Elevate™.

 

Patient Support Programs (PSPs), provided by pharmaceutical companies, are
designed to help patients manage their medical conditions alongside
prescription therapies by offering resources and tailored support. By
integrating Trellus Elevate™ into such a program, patients are offered the
tools and confidence to navigate the emotional and physical challenges of
their condition, stay engaged, adhere to treatment plans, and take control of
their health journey.

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:

"We identified the pharmaceutical sector as a key strategic vertical in our
September interim results and are excited to announce our first major
collaboration in this vertical. Trellus Elevate™ provides a seamless,
end-to-end solution from clinical trials to commercialisation, leveraging our
proprietary resilience-based approach to drive trial and patient support
success.

 

"We have reached a therapeutic ceiling with many existing treatments for IBD
and it is only by addressing both the mind and body that we can truly break
through that barrier. Managing and adhering to treatment regimens for
lifelong, incurable immune conditions like IBD can be overwhelming for
patients, making comprehensive support essential. By providing holistic
wraparound care, we can help patients stay on track with their therapies and
empower them to thrive. We look forward to working with Johnson & Johnson
and leveraging our Trellus Elevate™ platform and our innovative methodology
to help support patients' needs."

 

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310.  Upon the
publication of this announcement, this inside information is now considered to
be in the public domain.

 

For further information please contact:

 

 Trellus Health plc                                                 https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder         Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)              Tel: +44 (0)20 7496 3000
 Jen Boorer / James Todd / Jalini Kalaravy

 Walbrook PR                        Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                    (mailto:trellus@walbrookpr.com)
 Paul McManus / Phillip Marriage /  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082/

 Louis Ashe-Jepson                  +44 (0) 7747 515 393

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate™, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying Trellus Elevate™ resulted in over 90%
fewer hospitalisations and a reduction of over 70% in emergency room visits.
Given the common emotional and mental health struggles associated with a
variety of chronic conditions, Trellus Health considers its approach to have
potential utility and demand across many conditions.

 

Trellus Health® also offers a seamless solution for pharmaceutical partners
from clinical trials to commercialisation, harnessing resilience-based methods
to drive both trial and patient support success by empowering patients to stay
engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both world-leading experts at treating and healing
both the physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBIMFTMTIBMBA